Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC boosted its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 169.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,000 shares of the company's stock after purchasing an additional 12,579 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Revolution Medicines were worth $875,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. IFP Advisors Inc purchased a new position in shares of Revolution Medicines in the fourth quarter valued at $34,000. Sterling Capital Management LLC increased its holdings in Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after buying an additional 1,672 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Revolution Medicines by 368.3% during the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after buying an additional 1,613 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in Revolution Medicines by 521.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after buying an additional 3,178 shares during the last quarter. Finally, Avanza Fonder AB acquired a new stake in shares of Revolution Medicines during the fourth quarter worth $173,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Mark A. Goldsmith sold 11,738 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the transaction, the insider now owns 441,564 shares in the company, valued at $17,238,658.56. The trade was a 2.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now directly owns 115,006 shares in the company, valued at approximately $4,489,834.24. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,660 shares of company stock valued at $650,406 in the last ninety days. 8.00% of the stock is currently owned by corporate insiders.

Revolution Medicines Stock Down 4.5%

Shares of NASDAQ RVMD traded down $1.87 during trading on Tuesday, hitting $40.01. The company had a trading volume of 940,319 shares, compared to its average volume of 1,492,391. The stock has a fifty day simple moving average of $37.40 and a two-hundred day simple moving average of $43.36. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $62.40. The firm has a market capitalization of $7.45 billion, a price-to-earnings ratio of -11.14 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period in the previous year, the firm earned ($0.70) EPS. On average, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on RVMD shares. Guggenheim cut their price objective on shares of Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Stifel Nicolaus reduced their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright raised their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Needham & Company LLC reiterated a "buy" rating and set a $57.00 price target on shares of Revolution Medicines in a research report on Thursday, May 8th. Finally, Wedbush restated an "outperform" rating and issued a $67.00 price objective on shares of Revolution Medicines in a research report on Thursday, May 8th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Revolution Medicines currently has an average rating of "Buy" and an average price target of $67.17.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.